Shunsuke Tsuduki
Minato, 1058461, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 14 publications
Real-world comparison of enzalutamide and apalutamide in metastatic hormone-sensitive prostate cancer: a multi-institutional propensity score-matched analysis.
Journal: Japanese journal of clinical oncology
Published: November 20, 2025
Prognostic impact of lung metastasis in patients treated with androgen receptor signaling inhibitors for castration-sensitive prostate cancer: data from the ULTRA-Japan Consortium.
Journal: Japanese journal of clinical oncology
Published: July 28, 2025
Real-world Outcomes of Enfortumab Vedotin in Elderly Patients With Metastatic Urothelial Carcinoma.
Journal: Anticancer research
Published: June 27, 2025
Association of body mass index and tumor response in metastatic urothelial carcinoma treated with enfortumab vedotin: data from the ULTRA-Japan consortium.
Journal: International journal of clinical oncology
Published: November 10, 2024
Predicting time to castration resistance with androgen-receptor signaling inhibitors in hormone-sensitive prostate cancer: data from ULTRA-Japan Consortium.
Journal: International journal of clinical oncology
Published: June 21, 2024
Durable Response to Enfortumab Vedotin Compared to Re-challenging Chemotherapy in Metastatic Urothelial Carcinoma After Checkpoint Inhibitors.
Journal: Targeted oncology
Published: February 26, 2024
Predicting Objective Response of Pembrolizumab in Platinum-Refractory Urothelial Carcinoma Based on Neutrophil-Lymphocyte Ratio Fluctuation and Liver Metastases.
Journal: Oncology
Published: August 22, 2023
Prognostic Impact of Immune-Related Adverse Events as First-Line Therapy for Metastatic Renal Cell Carcinoma Treated With Nivolumab Plus Ipilimumab: A Multicenter Retrospective Study.
Journal: Clinical genitourinary cancer
Published: March 24, 2023
Serum C-reactive Protein Level Predicts Overall Survival for Clear Cell and Non-Clear Cell Renal Cell Carcinoma Treated with Ipilimumab plus Nivolumab.
Journal: Cancers
Published: October 18, 2022
Re-challenging chemotherapy after pembrolizumab in platinum-refractory urothelial carcinoma.
Journal: BJU international
Published: September 13, 2022
Concurrent palliative radiation with pembrolizumab for platinum-refractory urothelial carcinoma is associated with improved overall survival.
Journal: Clinical and translational radiation oncology
Published: August 26, 2022
Last Updated: 09/26/2026